Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.

Blood - 11 Nov 2021

Cramer Paula, Tausch Eugen, von Tresckow Julia, Giza Adam, Robrecht Sandra, Schneider Christof, Fürstenau Moritz, Langerbeins Petra, Al-Sawaf Othman, Pelzer Benedikt W, Fink Anna Maria, Fischer Kirsten, Wendtner Clemens-Martin, Eichhorst Barbara, Kneba Michael, Stilgenbauer Stephan, Hallek Michael

Abstract excerpt

Fifty-one of 189 evaluable patients from 3 prospective phase 2 trials evaluating a sequential targeted treatment had high-risk chronic lymphocytic leukemia (CLL) with a 17p deletion, TP53 mutation, or both. Twenty-seven patients started treatment with bendamustine debulking before induction and maintenance treatment, which was ibrutinib/ofatumumab (IO) in 21 patients, ibrutinib/obinutuzumab (IG) in 13, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Piperidines

Share to Progression-Free Survival

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 34086865
DOI: 10.1182/blood.2020010484
PMCID: PMC9642790

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.PMID 34086865Read ↗

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Semantic proximity Read ↗

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.Semantic proximity Read ↗

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.Semantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.Semantic proximity Read ↗

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib.Semantic proximity Read ↗

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.Semantic proximity Read ↗

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.Semantic proximity Read ↗

TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?Semantic proximity Read ↗

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.Semantic proximity Read ↗

Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.